{
    "clinical_study": {
        "@rank": "13330", 
        "arm_group": {
            "arm_group_label": "dabigatran etexilate mesylate", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate major adverse bleeding risks, and thromboembolic\n      event rates post radiofrequency (RF) ablation. The primary goal is to establish safety of\n      dabigatran use for peri-procedural anti-coagulation after left atrial catheter\n      radiofrequency ablation, or cryoablation procedures."
        }, 
        "brief_title": "Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Atrial Flutter"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Atrial Flutter", 
                "Thromboembolism"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female sex, age 18-85 years.\n\n          -  Negative pregnancy test for women of childbearing potential\n\n          -  Planned pulmonary vein isolation by antral radiofrequency or cryoablation for\n             paroxysmal or persistent atrial fibrillation, non-valvular atrial fibrillation\n             (NVAF), or left atrial flutter following prior left atrial ablation procedures\n\n          -  CHADS2 score of 0-6 or CHADS2-VASc score 0-9\n\n          -  Vascular hemostasis within 4-6 hours of sheath pull\n\n          -  Able to give informed consent\n\n        Exclusion Criteria:\n\n          -  Unable to give informed consent\n\n          -  Currently participating in another clinical treatment trial\n\n          -  History of hereditary hemophilias\n\n          -  Presence of active bleeding\n\n          -  End stage renal disease, CrCl<15 mL/min\n\n          -  Prior treatment failure of dabigatran (stroke or systemic thromboembolism while on\n             therapeutic dabigatran)\n\n          -  Known allergic reaction to dabigatran etexilate\n\n          -  Intolerance to dabigatran, if medication na\u00efve, or other contra-indications as per\n             the USPI.\n\n          -  Pregnancy\n\n          -  History of non-compliance\n\n          -  Inability to follow-up"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01976507", 
            "org_study_id": "121204"
        }, 
        "intervention": {
            "arm_group_label": "dabigatran etexilate mesylate", 
            "intervention_name": "dabigatran etexilate mesylate", 
            "intervention_type": "Drug", 
            "other_name": "Pradaxa"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "contact": {
                "email": "christopher.ellis@vanderbilt.edu", 
                "last_name": "Christopher Ellis, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37232"
                }, 
                "name": "Vanderbilt University Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "Christopher R Ellis, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Sean P Whalen, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-permanent) Atrial Fibrillation and Left Atrial Flutter", 
        "overall_contact": {
            "last_name": "Sherry Bowman, RN", 
            "phone": "615-875-5500"
        }, 
        "overall_official": {
            "affiliation": "Vanderbilt University", 
            "last_name": "Christopher R Ellis, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency of major bleeding complications and thrombo-embolic events in patients administered dabigatran following RF ablation.", 
            "safety_issue": "Yes", 
            "time_frame": "Within 4 months following procedure (+/- 4 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01976507"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Vanderbilt University", 
            "investigator_full_name": "Christopher Ellis", 
            "investigator_title": "Assistant Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Dabigatran serum drug levels in patients experiencing a major bleeding or thrombo-embolic event.", 
                "safety_issue": "Yes", 
                "time_frame": "Within 4 months following procedure (+/- 4 days)"
            }, 
            {
                "measure": "Frequency of minor bleeding events", 
                "safety_issue": "Yes", 
                "time_frame": "Within 4 months following procedure (+/- 4 days)"
            }
        ], 
        "source": "Vanderbilt University", 
        "sponsors": {
            "collaborator": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Vanderbilt University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}